Market Research Report
Pulmonary Arterial Hypertension - Global Drug Forecast and Market Analysis to 2029
|Published by||GlobalData||Product code||963042|
Delivery time: 1-2 business days
|Pulmonary Arterial Hypertension - Global Drug Forecast and Market Analysis to 2029|
|Published: September 30, 2020||Content info:||
Pulmonary arterial hypertension is a rare, fatal cardiopulmonary disease with an annual mortality rate around 10%. The disease is a subset (Group 1) within the World Health Organization's (WHO's) classification of the different types of pulmonary hypertension. PAH is characterized by an abnormal rise in the resting mean pulmonary artery pressure (PAP) (>25mmHg compared with normal levels of around 14mmHg), a pulmonary vascular resistance of more than 3 Wood units, and a pulmonary capillary wedge pressure less than 15mmHg
The PAH market 2019 sales is estimated at approximately $4.5B across the 7MM, encompassing the US, the five major European countries (5EU: France, Germany, Italy, Spain, and UK), and Japan. By 2029, GlobalData expects the overall market to grow at a moderate compound annual growth rate (CAGR) of 4.9% to reach sales of $7.2B over the 10-year period. The 5EU market is anticipated to grow the fastest of the three regions, recording a CAGR of 7.3%, while the US and Japan will record CAGRs of 4.3% and 0.4%, respectively. At the end of 2029, the US will contribute around 72% of global sales, while the 5EU and Japan will account for 26% and 2% of global sales, respectively. The higher sales numbers for the US can be attributed to the higher price of pharmaceuticals and the greater diagnosed prevalence of PAH in the region. The extremely low PAH market size in Japan can be attributed to the low disease prevalence, which is probably a result of under-diagnosis of PAH in Japan.
Over the 10-year forecast period, the PAH market is expected to grow at a compound annual growth rate (CAGR) of 4.9%, reaching around $7.2B in 2029. The major driver for this growth will be the increased use of drugs from different classes in combination with each other, which will lead to increased treatment costs. According to KOLs, combination therapy will become a mainstay in PAH treatment during the forecast period, with greater use of upfront dual and triple combinations. This, in turn, will be the major driver of the market, despite the patent expirations of most currently marketed drugs and generic erosion.
Overall, the greatest unmet need in the PAH space is for novel drugs with curative or disease-stabilizing properties. The currently available drugs work in slowing the disease progression, and lead to improvements in FC. However, there is no marketed drug that addresses the underlying disease mechanism and is targeted at curing patients. The treatment algorithm for PAH has shifted from the use of monotherapies to using drugs in combination with each other
Despite the existence of numerous well-established treatment options in the PAH space, a few - yet significant - unmet needs remain.
The PAH market hasn't seen novel drug launches, though, clinical development activity has picked up.
Although there is currently no cure for PAH, small companies are developing drugs to target new pathways .
The report will enable you to -